Drug Trial Radar · NCT07611162
Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux Disease
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
May 1, 2030
Study completion May 1, 2030
Sponsor
- Lead sponsor
- University of MonsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized controlled trial is to compare the effectiveness of different treatments for laryngopharyngeal reflux disease (LPRD) in adult patients with confirmed symptoms and signs of the condition. The main question it aims to answer is: Which treatment (Proton Pump Inhibitors (PPIs), alginate, magaldrate, sucralfate, or diet) leads to the greatest improvement in LPRD symptoms and clinical signs over 3 months? Researchers will compare proton pump inhibitors to alternative medical treatments and dietary management to see which approach is most effective and better tolerated. Participants will: * undergo a clinical ENT examination with scoring of reflux signs (RSA) * complete symptom questionnaires (RSS) assessing severity, frequency, and impact of symptoms * receive one of the study treatments (medication or dietary intervention) * be evaluated at baseline and again after 3 months of treatment
Conditions
- Laryngopharyngeal Reflux Disease
Interventions
AlginateDrug
Use of Gaviscon anti-acid, anti-reflux
MagaldrateDrug
use of Riopan drug
SucralfateDrug
use of Kéal sucralfate
Proton Pump Inhibitor (PPI) TherapyDrug
Use of Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole
DietBehavioral
Patients are recommended to adhere to a 3-month low-fat, low quick-release sugar, high-protein, alkaline, and plant-based diet. The consumption of fish and meat was authorized but reduced to low-fat fish and meat. The anti-reflux diet considered the exclusion/reduction of additional triggers such as caffeine or theine, spices, tomatoes, fatty, cheese alcohol, and sparkling beverages.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the effectiveness of each intervention based on changes in Reflux Symptom Score (RSS) and Reflux Sign Assessment (RSA) from pre- to post-treatment follow-up.Time frame: From enrollment to the end of treatment at 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Mons
Mons, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.